粒细胞-巨噬细胞集落刺激因子分泌型白血病细胞疫苗用于异基因造血干细胞移植后骨髓增生异常综合征/急性髓系白血病:一项随机双盲2期试验
该随机双盲2期试验将123例骨髓增生异常综合征伴原始细胞过多或复发/难治急性髓系白血病患者随机分配至GVAX或安慰剂组,92例接受移植,57例(GVAX组30例、安慰剂组27例)接受至少1次疫苗接种。中位随访39个月,GVAX未改善无进展生存、总生存或复发率,注射部位反应在GVAX组更常见(10例 vs 1例,P=0.006)。
要点
- GVAX组与安慰剂组18个月无进展生存率分别为53%和55%(P=0.79),总生存率分别为63%和59%(P=0.86),复发率分别为30%和37%(P=0.51)。
- GVAX组注射部位反应更常见(10例 vs 1例,P=0.006),未报告Common Toxicity Criteria 3级或更严重的疫苗相关不良事件。
- GVAX未降低或增强T细胞、B细胞和自然杀伤细胞的重建,两组血清主要组织相容性链相关蛋白A/B及其他免疫生物标志物无差异。
核心结论
- GVAX不能改善骨髓增生异常综合征/急性髓系白血病异基因造血干细胞移植后的生存。
研究设计与样本
- 随机双盲2期试验,纳入123例骨髓增生异常综合征伴原始细胞过多或复发/难治急性髓系白血病患者,按疾病、移植中心和预处理方案分层,以1:1随机分配至GVAX组或安慰剂组。
- 移植前采集原始粒细胞制备疫苗,移植后第30至45天之间若植入成功且无移植物抗宿主病则开始接种,皮下/皮内注射每周3次,随后每2周3次。
- 92例患者接受移植,57例(GVAX组30例、安慰剂组27例)接受至少1次疫苗接种;中位随访39个月(范围9-89个月)。
主要发现
- 18个月无进展生存率GVAX组53% vs 安慰剂组55%(P=0.79),总生存率GVAX组63% vs 安慰剂组59%(P=0.86),复发率GVAX组30% vs 安慰剂组37%(P=0.51)。
- 18个月非复发死亡率GVAX组17% vs 安慰剂组7.7%(P=0.18),12个月II至IV级急性移植物抗宿主病发生率GVAX组34% vs 安慰剂组12%(P=0.13),3年慢性移植物抗宿主病发生率GVAX组49% vs 安慰剂组57%(P=0.26)。
- 注射部位反应在GVAX组更常见(10例 vs 1例,P=0.006),未报告Common Toxicity Criteria 3级或更严重的疫苗相关不良事件。
- GVAX未降低或增强T细胞、B细胞和自然杀伤细胞的重建,两组血清主要组织相容性链相关蛋白A/B及其他免疫生物标志物无差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination using irradiated, adenovirus transduced autologous myeloblasts to secrete granulocyte-macrophage colony-stimulating factor (GVAX) early after allogeneic hematopoietic stem cell transplantation (HSCT) can induce potent immune responses. We conducted a randomized phase 2 trial of GVAX after HSCT for myelodysplastic syndrome with excess blasts or relapsed/refractory acute myeloid leukemia. Myeloblasts were harvested before HSCT to generate the vaccine. Randomization to GVAX vs placebo (1:1) was stratified according to disease, transplant center, and conditioning. Graft-versus-host disease (GVHD) prophylaxis included tacrolimus and methotrexate. GVAX or placebo vaccination was started between day 30 and 45 if there was engraftment and no GVHD. Vaccines were administered subcutaneously/intradermally weekly × 3, then every 2 weeks × 3. Tacrolimus taper began after vaccine completion. A total of 123 patients were enrolled, 92 proceeded to HSCT, and 57 (GVAX, n = 30; placebo, n = 27) received at least 1 vaccination. No Common Toxicity Criteria grade 3 or worse vaccine-related adverse events were reported, but injection site reactions were more common after GVAX (10 vs 1; P = .006). With a median follow-up of 39 months (range, 9-89 months), 18-month progression-free survival, overall survival, and relapse incidence were 53% vs 55% (P = .79), 63% vs 59% (P = .86), and 30% vs 37% (P = .51) for GVAX and placebo, respectively. Nonrelapse mortality at 18 months was 17% vs 7.7% (P = .18), grade II to IV acute GVHD at 12 months was 34% vs 12% (P = .13), and chronic GVHD at 3 years was 49% vs 57% for GVAX and placebo (P = .26). Reconstitution of T, B, and natural killer cells was not decreased or enhanced by GVAX. There were no differences in serum major histocompatibility chain-related protein A/B or other immune biomarkers between GVAX and placebo. GVAX does not improve survival after HSCT for myelodysplastic syndrome/acute myeloid leukemia. This trial was registered at www.clinicaltrials.gov as #NCT01773395.
引用
- Ho VT, Kim HT, Brock J, et al. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Adv. 2022. PMID: 34807983. doi:10.1182/bloodadvances.2021006255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。